CHNA

Loncar China BioPharma ETF
F

--
*Unless otherwise stated, data provided by FactSet.

CHNA Fund Description

CHNA tracks a tier-weighted index of companies directly involved in the growth of China’s pharmaceutical and biotech industry.

CHNA Factset Analytics Insight

CHNA targets China’s pharmaceutical and biotech (biopharma) sector. The fund includes pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers or distributors of biopharma products, and biopharma service providers. It is worth noting that manufacturers of pharmaceutical ingredients are excluded, as the fund focuses on innovation in the sector. CHNA uses a tiered weighting system. Starting from equal weight, all qualified constituents are assigned a weight adjustment based on market cap. Large cap stocks get a 140% adjustment, midcaps 100%, and small-caps 70%. For this exposure, CHNA charge a fee in line with its closest competitors, although still at a price worth consideration.

CHNA MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of April 18, 2019 the Loncar China BioPharma ETF MSCI ESG Fund Quality Score is 3.94 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. CHNA ranks in the 67th percentile within its peer group and in the 8th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

CHNA CHARTS AND PERFORMANCE

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:
PERFORMANCE [as of 04/18/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
CHNA 3.65% 15.35% 26.34% -- -- -- --
CHNA (NAV) 3.91% 16.92% 28.00% -- -- -- --
Loncar China BioPharma Index 3.95% 17.11% 28.33% -7.20% -- -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

CHNA Top 10 Countries

CHNA Top 10 Sectors

CHNA Top 10 Holdings [View All]

CHNA Summary Data

Loncar
08/14/18
Open-Ended Fund
0.79%
$3.67M
$100.17K
0.50%

CHNA Portfolio Data

$4.93B
31.33
2.74
--
N/A
25

CHNA Index Data

Loncar China BioPharma Index
Tiered
Market Cap
N/A

CHNA Portfolio Management

0.79%
--
--
--

CHNA Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

CHNA Fund Structure

Open-Ended Fund
No
No
No Policy
N/A
N/A
High
Daily
Cboe Book Viewer
TOP OF BOOK
LAST 10 TRADES
Bats BZX Real-time Quote -
Daily Spread
Premium/Discount
Volume

CHNA Factset Analytics Block Liquidity

As of 04/19/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of CHNA. CHNA is rated a 1 out of 5.

CHNA Tradability

4,052
$100.17K
1,810
$44.03K
0.50%
$0.11
0.61%
3.11% / -1.97%
None
21.00%
25,000
0.07
0.12%
1.64%
--
$24.18
1

CHNA Sector/Industry Breakdown


CHNA
Segment Benchmark
53.18%
--
11.00%
--
9.18%
--
4.51%
--
2.91%
--
2.89%
--

CHNA TOP 10 HOLDINGS[View All]

5.38%
5.15%
4.88%
4.60%
3.77%
3.70%
3.67%
3.67%
3.65%
42.49%

CHNA Countries


CHNA
Segment Benchmark
82.45%
--
9.43%
--
4.51%
--
3.61%
--

CHNA Regions


CHNA
Segment Benchmark
86.06%
--
9.43%
--
4.51%
--

CHNA Economic Development


CHNA
Segment Benchmark
96.39%
--
3.61%
--

CHNA Performance Statistics

--
--
--
--
0.00%
N/A

CHNA MSCI ESG Ratings

3.94 / 10
67.23
7.54
--
14.40%
35.10

CHNA BENCHMARK COMPARISON HOLDINGS

25
--
--
0.00%

CHNA BENCHMARK COMPARISON SUMMARY


CHNA
Segment Benchmark
25
--
$4.93B
--
31.33
--
2.74
--
1.16%
--
High
High

CHNA BENCHMARK COMPARISON MARKET CAP SIZE


CHNA
Segment Benchmark
0.00%
--
64.04%
--
24.04%
--
11.93%
--